PharmaSeq

Home Company News & Events Press Releases 2015 National Human Genome Research Institute Awards SBIR Grant to PharmaSeq for DNA Synthesis

Press Releases

National Human Genome Research Institute Awards SBIR Grant to PharmaSeq for DNA Synthesis

Monmouth Junction, NJ, September 14, 2015.PharmaSeq, Inc., announced today the receipt of a significant SBIR grant for a project titled “Genome-scale De Novo Synthesis on Electronic p-Chips with Sorting.” The grant was awarded by the National Human Genome Research Institute (NHGRI), one of the U.S. National Institutes of Health. The award is for Phase I of a larger project that is anticipated to next include Phase II activities under the SBIR’s “Fast-Track” program.

The grant’s objective is to develop technology that includes improved methods and instrumentation for manufacturing large numbers of synthetic DNAs (oligonucleotides). These oligonucleotides will be used to assemble large libraries of double-stranded DNA fragments that span long stretches of chromosomes. Such fragments can then be used to reconstruct genomes with any desired sequence. Large numbers of synthetic oligonucleotides can also be used in research and diagnostic applications, including targeted DNA sequencing and multiplex DNA assays. PharmaSeq projects that the costs per nucleotide using its approach will be much less than those of current methods.

The electronic p-Chip®, invented and developed by PharmaSeq, will serve as the solid phase support on which DNA synthesis takes place. The key enabler of the Company’s approach is a high-speed sorter. Because every synthesized sequence is affixed to a p-Chip with a unique ID, p-Chips can be sorted according to their ID, allowing for unprecedented sequence-directed combinatorial synthesis of the oligonucleotides. On each pass through the sorter, p-Chips are directed into one of four reservoirs (A, C, G or T) according to the next base that is to be appended to the growing DNA chain. This enables the construction of large and complex nucleic acid libraries.

“The migration of DNA synthesis from traditional polymer substrates to p-Chips has the potential to accelerate research and reduce costs in the emerging field of synthetic genomics,” states Wlodek Mandecki, Ph.D., President and Chief Scientific Officer of PharmaSeq. Dr. Mandecki adds, “The ability to rapidly produce very high fidelity sequences using sequence-directed combinatorial DNA synthesis is a game-changer for the field. The fact that sequences will be attached to the p-Chip following synthesis provides the ability to construct large biorepositories of nucleic acid sequences for research and applied applications.”

For further information, please contact Richard G. Morris, Ph.D., CEO, or Dr. Mandecki at (732) 355-0100 ext. 11.

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852


Download as PDF

 

Home Company News & Events Press Releases 2015 National Human Genome Research Institute Awards SBIR Grant to PharmaSeq for DNA Synthesis